CCXI - CCXI STOCK NEWS

ChemoCentryx announced significant advancements in its pipeline, including the acceptance of a New Drug Application (NDA) by the FDA for avacopan, aimed at treating ANCA-associated vasculitis, with a PDUFA goal date of July 7, 2021. The European Medicines Agency has validated the Marketing Authorization Application (MAA) for the same indication. Upcoming topline data from the ACCOLADE trial for C3 Glomerulopathy is expected by year-end 2020. Financially, the company reported Q3 2020 revenue of $5.1 million, down from $10.6 million in Q3 2019, with a net loss of $24.1 million.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced today at ACR Convergence 2020 Phase III trial results for its drug candidate avacopan, highlighting its effectiveness in treating ANCA-associated vasculitis. Avacopan achieved statistical superiority over standard prednisone therapy, sustaining remission at 52 weeks and improving renal function. The FDA is currently reviewing a New Drug Application (NDA) for avacopan, with a goal date set for July 7, 2021. The ADVOCATE trial involved 331 patients across 20 countries, showcasing avacopan's potential for better long-term outcomes.

ChemoCentryx and Vifor Fresenius Medical Care have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for avacopan, targeting ANCA-associated vasculitis. This submission follows positive results from the Phase-III ADVOCATE trial, demonstrating avacopan's superiority in sustaining remission at 52 weeks when compared to traditional prednisone treatment. Avacopan would become the first oral selective complement receptor inhibitor for this condition if approved, with a decision expected in H2 2021.

ChemoCentryx (NASDAQ: CCXI) will release its third quarter 2020 financial results on November 9, 2020, after market close. A conference call and webcast for investors will follow at 5:00 p.m. ET the same day. The company focuses on developing drugs for autoimmune and inflammatory diseases, with its lead candidate, avacopan (CCX168), under FDA review after a successful Phase III trial for ANCA-associated vasculitis. Avacopan is also being tested for Hidradenitis Suppurativa and C3 glomerulopathy.

ChemoCentryx (Nasdaq: CCXI) released positive topline results from the Phase II AURORA trial of avacopan, a treatment for Hidradenitis Suppurativa (HS). The trial involved 398 patients, showing statistically significant improvement in the HiSCR response among Hurley Stage III patients treated with avacopan 30 mg BID versus placebo. Avacopan was also well-tolerated with fewer treatment-emergent adverse events. The company plans to advance avacopan into Phase III development targeting severe HS patients, aiming to address the limited treatment options available for this condition.

ChemoCentryx (Nasdaq: CCXI) announced that the FDA has accepted its New Drug Application (NDA) for avacopan, a selective complement 5a receptor inhibitor for treating ANCA-associated vasculitis, with a PDUFA goal date set for July 7, 2021. The NDA includes data from the Phase III ADVOCATE trial, which showed avacopan's superiority in sustaining remission and lower glucocorticoid toxicity compared to prednisone. Avacopan is positioned as a first-in-class therapy with favorable safety results, targeting inflammation without the extensive side effects of traditional treatments.

MOUNTAIN VIEW, Calif., Sept. 8, 2020 – ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall, Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 1:30 p.m. ET. A live audio webcast will be available on the company’s website and a replay will be accessible for two weeks post-presentation. ChemoCentryx focuses on developing targeted therapies for inflammatory and autoimmune diseases and cancer, with its lead drug candidate avacopan undergoing FDA review following a pivotal Phase III trial.

ChemoCentryx (Nasdaq: CCXI) is set to release its second quarter 2020 financial results on August 10, 2020, after market close. An executive management conference call will follow at 5:00 p.m. Eastern Time to discuss the results. Interested participants can join via phone or access a live and archived audio webcast through ChemoCentryx’s website. The company focuses on developing medications for inflammatory, autoimmune diseases, and cancer, with its lead drug candidate, avacopan (CCX168), having completed a pivotal Phase III trial in ANCA-associated vasculitis.

ChemoCentryx (NASDAQ: CCXI) has announced the identification of CCX559, an orally administered checkpoint inhibitor, with plans to start clinical development in early 2021. Data presented at the AACR meeting revealed that their optimized inhibitors significantly blocked the PD-1/PD-L1 interaction, showing strong anti-tumor effects in animal models. The company aims to develop more convenient and safe therapies to enhance immune responses against tumors, potentially complementing existing antibody therapies.